Home | All trials

[RDF data]
Trial NCT00000179

Resource URI: http://static.linkedct.org/resource/trials/NCT00000179
PropertyValue
linkedct:brief_title Agitation in Alzheimer's Disease
linkedct:condition <http://static.linkedct.org/resource/condition/829>
linkedct:criteria Inclusion Criteria: - Memory problem consistent with a probable diagnosis of Alzheimer's disease (AD) - Agitation symptoms for at least the past 2 weeks - Patient has caregiver who can participate - Patient lives in the same household as the caregiver
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age N/A
linkedct:eligibility_minimum_age 50 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date October 29, 1999
linkedct:id NCT00000179
rdfs:label Trial NCT00000179
linkedct:lastchanged_date June 23, 2005
linkedct:lead_sponsor_agency National Institute on Aging (NIA)
linkedct:location <http://static.linkedct.org/resource/location/147072>
linkedct:location <http://static.linkedct.org/resource/location/153094>
linkedct:location <http://static.linkedct.org/resource/location/153764>
linkedct:location <http://static.linkedct.org/resource/location/157178>
linkedct:location <http://static.linkedct.org/resource/location/170541>
linkedct:location <http://static.linkedct.org/resource/location/173811>
linkedct:location <http://static.linkedct.org/resource/location/174084>
linkedct:location <http://static.linkedct.org/resource/location/181169>
linkedct:location <http://static.linkedct.org/resource/location/182698>
linkedct:location <http://static.linkedct.org/resource/location/186363>
linkedct:location <http://static.linkedct.org/resource/location/190347>
linkedct:location <http://static.linkedct.org/resource/location/193875>
linkedct:location <http://static.linkedct.org/resource/location/195834>
linkedct:location <http://static.linkedct.org/resource/location/210838>
linkedct:location <http://static.linkedct.org/resource/location/213264>
linkedct:location <http://static.linkedct.org/resource/location/218752>
linkedct:nct_id NCT00000179
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:org_study_id IA0003
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/34878>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000179>
linkedct:phase Phase 3
linkedct:results_reference <http://static.linkedct.org/resource/results_reference/2359>
linkedct:secondary_id 3U01AG10483-08S2
linkedct:source National Institute on Aging (NIA)
linkedct:study_design Treatment, Randomized, Double-Blind, Placebo Control
linkedct:study_type Interventional
linkedct:summary Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective.
rdf:type linkedct:trials
linkedct:verification_date March 2005